Pannexin 1 (PNX1); purinergic receptor P2Y G protein–coupled 2 (P2RY2; P2Y2); protein tyrosine kinase 2β (PTK2B; PYK2) BriefCommunication Pages: 992 - 992
Adrenergic receptor β2 (ADRB2); muscarinic acetylcholine receptor M3 (CHRM3; HM3) BriefCommunication Pages: 994 - 994
Peroxisome proliferation–activated receptor-γ (PPARG; PPARγ); cyclin dependent kinase 5 (CDK5) BriefCommunication Pages: 995 - 995
Target detection using DNA-based sensors and personal glucose meters BriefCommunication Pages: 996 - 996
Repositioning drug indications with parallel analysis of disease and drug gene expression signatures BriefCommunication Pages: 997 - 997
Lipid-substituted polyethylenimine (PEI)-mediated therapeutic small interfering RNA delivery BriefCommunication Pages: 999 - 999
In vitro generation of cancer stem cells (CSCs) and selection based on fucosyltransferase 4 α1,3-fucosyltransferase myeloid-specific (FUT4; CD15; SSEA-1) BriefCommunication Pages: 1000 - 1000
Combined radioactive and fluorescent imaging agent that binds prostate-specific membrane antigen (PSMA; FOLH1; GCPII) BriefCommunication Pages: 1001 - 1001
Detection of Staphylococcus aureus endocarditis with fluorescent or radiolabeled prothrombin analogs BriefCommunication Pages: 1002 - 1002
BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) expression as a predictor of cancer response to kinase inhibitor therapy BriefCommunication Pages: 1003 - 1003
NMDA receptor NR2A subtype (GRIN2A; NR2A) genotype as a marker for responsiveness to Parkinson's disease (PD) therapeutics BriefCommunication Pages: 1004 - 1004